New compounds and their mixtures enable the formation of the ferroelectric nematic liquid crystalline phase at ambient temperature. Compounds of the formula I are presented,

##STR00001## in which the variable groups have the meanings indicated in claim 1. Liquid crystal media comprise at least one compound of the formula I.

The invention relates to bimesogenic compounds of formula I ##STR00001##
wherein R.sup.11, R.sup.12, MG.sup.11, MG.sup.12, X.sup.11, X.sup.12 and Sp.sup.1 have the meaning given in claim 1, to the use of bimesogenic compounds of formula l in liquid crystal media and particular to flexoelectric liquid crystal devices comprising a liquid crystal medium according to the present invention.

The invention relates to bimesogenic compounds of formula I ##STR00001##
wherein R.sup.11, R.sup.12, MG.sup.11, MG.sup.12, X.sup.11, X.sup.12 and Sp.sup.1 have the meaning given in claim 1, to the use of bimesogenic compounds of formula l in liquid crystal media and particular to flexoelectric liquid crystal devices comprising a liquid crystal medium according to the present invention.

Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.

Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.

The invention relates to bimesogenic compounds of formula I

##STR00001##

wherein R.sup.11, R.sup.12, MG.sup.11, MG.sup.12, X.sup.11, X.sup.12 and Sp.sup.1 have the meaning given in claim 1, to the use of bimesogenic compounds of formula I in liquid crystal media and particular to flexoelectric liquid crystal devices comprising a liquid crystal medium according to the present invention.

The invention relates to bimesogenic compounds of formula I

##STR00001##

wherein R.sup.11, R.sup.12, MG.sup.11, MG.sup.12, X.sup.11, X.sup.12 and Sp.sup.1 have the meaning given in claim 1, to the use of bimesogenic compounds of formula I in liquid crystal media and particular to flexoelectric liquid crystal devices comprising a liquid crystal medium according to the present invention.

Method of improving the performance and safety of a Li-ion battery. The method includes using a nitrile-based small organic compound of general formula I, V or IX outlined in the application in association with the electrolyte of the battery. An electrolyte including a nitrile-based small organic compound. A battery including the electrolyte.

Method of improving the performance and safety of a Li-ion battery. The method includes using a nitrile-based small organic compound of general formula I, V or IX outlined in the application in association with the electrolyte of the battery. An electrolyte including a nitrile-based small organic compound. A battery including the electrolyte.

A compound that is suitably used for formation of an optically anisotropic film having excellent reverse wavelength dispersibility and moisture-heat resistance; a polymerizable composition; an optically anisotropic film; an optical film; a polarizing plate; and an image display device. The present invention relates to a compound represented by Formula (I-1) P.sup.1-SP.sup.1-Ar.sup.1-Mes-Ar.sup.2-SP.sup.2-P.sup.2 (I-1).